Cancer stem cells-emanated therapy resistance: Implications for liposomal drug delivery systems

Dianat‐Moghadam, Hassan; Heidarifard, Maryam; Jahanban‐Esfahlan, Rana; Panahi, Yunes; Hamishehkar, Hamed; Pouremamali, Farhad; Rahbarghazi‬, Reza; Nouri, Mohammad

doi:10.1016/j.jconrel.2018.08.043

Cited by 115 publications

(100 citation statements)

References 192 publications

Supporting

Mentioning

100

Contrasting

Order By: Relevance

“…[27,28] Recently, liposomal drug delivery systems have been proposed for targeting cancer stem cells to overcome drug resistance. [29] Thus, much effort has been made for increasing the delivery and penetration of liposomal-carried drugs into tumors, [30][31][32][33] including NB. [34][35][36][37][38] Although the so-called "enhanced permeability and retention effect" (owing to leaky vessels typically present in tumors) has served as a rationale for using nanoformulated drugs to treat solid tumors, it is generally believed that this effect is not sufficient to guarantee uniform drug delivery to all tumor regions, because of the many physiological barriers, mentioned above, present in tumor tissues.…”

Section: Liposomal Drugsmentioning

confidence: 99%

“…These features, together with the lack of lymphatic vessels and transient vascular compression by proliferating cancer cells, can lead to increased vascular leakage, high interstitial pressure, irregular blood flow, and heterogeneous permeability, i.e., a series of abnormalities that may cause uneven drug penetration in tumors . Recently, liposomal drug delivery systems have been proposed for targeting cancer stem cells to overcome drug resistance …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Overcoming Biological Barriers in Neuroblastoma Therapy: The Vascular Targeting Approach with Liposomal Drug Nanocarriers

Pastorino

Brignole

Paolo

et al. 2019

Small

View full text Add to dashboard Cite

Neuroblastoma is a rare pediatric cancer characterized by a wide clinical behavior and adverse outcome despite aggressive therapies. New approaches based on targeted drug delivery may improve efficacy and decrease toxicity of cancer therapy. Furthermore, nanotechnology offers additional potential developments for cancer imaging, diagnosis, and treatment. Following these lines, in the past years, innovative therapies based on the use of liposomes loaded with anticancer agents and functionalized with peptides capable of recognizing neuroblastoma cells and/or tumor‐associated endothelial cells have been developed. Studies performed in experimental orthotopic models of human neuroblastoma have shown that targeted nanocarriers can be exploited for not only decreasing the systemic toxicity of the encapsulated anticancer drugs, but also increasing their tumor homing properties, enhancing tumor vascular permeability and perfusion (and, consequently, drug penetration), inducing tumor apoptosis, inhibiting angiogenesis, and reducing tumor glucose consumption. Furthermore, peptide‐tagged liposomal formulations are proved to be more efficacious in inhibiting tumor growth and metastatic spreading of neuroblastoma than nontargeted liposomes. These findings, herein reviewed, pave the way for the design of novel targeted liposomal nanocarriers useful for multitargeting treatment of neuroblastoma.

show abstract

Section: Liposomal Drugsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Overcoming Biological Barriers in Neuroblastoma Therapy: The Vascular Targeting Approach with Liposomal Drug Nanocarriers

Pastorino

Brignole

Paolo

et al. 2019

Small

View full text Add to dashboard Cite

show abstract

“…CSCs has been studied as a prospectively curative approach against a variety of malignancies. [4][5][6] We found that Cygb knockdown aggravates the formation of HCC sphere, whereas Cygb restoration inhibits the formation of HCC sphere in vitro (Figure 2E-H). CD133…”

Section: Cscs Are a Crucial Subpopulation Of Cancer Cells Targetingmentioning

confidence: 89%

“…Cancer stem cells (CSCs) are the crucial subpopulation of cancer cells that determine tumor initiation, self‐renewal, and heterogeneity. Targeting CSCs may provide a curative approach to overcome therapy resistance and prevent tumor progression . Accumulating evidences indicated that the interaction of ONS with CSCs promotes tumorigenesis, progression and cancers resistance to chemoradiotherapies.…”

Section: Introductionmentioning

confidence: 99%

Cytoglobin ameliorates the stemness of hepatocellular carcinoma via coupling oxidative‐nitrosative stress signals

Zhang

Pei

Yang

et al. 2018

Molecular Carcinogenesis

View full text Add to dashboard Cite

Cancer stem cells (CSCs) account for tumor self‐renewal and heterogeneity. Oxidative‐nitrosative stress (ONS) is an independent etiologic factor throughout tumorigenesis. Emerging evidences indicated that the interaction of ONS with CSCs contributes to tumor progression and resistance to chemoradiotherapy. Cytoglobin (Cygb) is a member of human hexacoordinate hemoglobin family and acts as a dynamic mediator of redox homeostasis. We observed that Cygb is significantly deregulated in human hepatocellular carcinoma (HCC) tissue and its decrease aggravates the growth of liver cancer stem cells (LCSCs) and increases the subpopulation of CD133(+) LCSCs. Cygb restoration inhibits HCC proliferation and LCSC growth, and decreases the subpopulation of CD133 (+) LCSCs in vitro. We found that Cygb absence promotes LCSC phenotypes and PI3 K/AKT activation, whereas Cygb restoration inhibits LCSC phenotypes and PI3 K/AKT activation. Furthermore, exogenous antioxidants can eliminate the inhibitory effect of Cygb to LCSC growth and phenotypes, as well as PI3 K/AKT activation. Collectively, this study demonstrated that cytoglobin functions as a tumor suppressor and targets CSCs at an ONS‐dependent manner. Thus, Cygb restoration could be a novel and promising therapeutic strategy against HCC with aberrant ROS/RNS accumulation.

show abstract

“…Giant liposomes could be utilized to create artificial model cells, as well as to detect, and analyze protein production (Sunami et al, 2009). Integrating various reaction networks and optimizing their scalability and flexibility can be achieved through the use of liposomes, which provides the advantage for the chemical reactions to take place within encapsulated environments (Dianat‐Moghadam et al, 2018). The pivot on which developing minimal cells through bottom‐up synthetic biology methods are based is the reconstitution of an essential gene expression system within lipid vesicles that are self‐assembled to imitate the cellular synthesis machinery (Amidi et al, 2010).…”

Section: Cfps: Latest Platforms and Applications In Biotechnology Andmentioning

confidence: 99%

Cell‐free protein synthesis: The transition from batch reactions to minimal cells and microfluidic devices

Ayoubi‐Joshaghani

Dianat‐Moghadam

Seidi

et al. 2020

Biotech & Bioengineering

View full text Add to dashboard Cite

Thanks to the synthetic biology, the laborious and restrictive procedure for producing a target protein in living microorganisms by biotechnological approaches can now experience a robust, pliant yet efficient alternative. The new system combined with lab‐on‐chip microfluidic devices and nanotechnology offers a tremendous potential envisioning novel cell‐free formats such as DNA brushes, hydrogels, vesicular particles, droplets, as well as solid surfaces. Acting as robust microreactors/microcompartments/minimal cells, the new platforms can be tuned to perform various tasks in a parallel and integrated manner encompassing gene expression, protein synthesis, purification, detection, and finally enabling cell‐cell signaling to bring a collective cell behavior, such as directing differentiation process, characteristics of higher order entities, and beyond. In this review, we issue an update on recent cell‐free protein synthesis (CFPS) formats. Furthermore, the latest advances and applications of CFPS for synthetic biology and biotechnology are highlighted. In the end, contemporary challenges and future opportunities of CFPS systems are discussed.

show abstract

Cancer stem cells-emanated therapy resistance: Implications for liposomal drug delivery systems

Cited by 115 publications

References 192 publications

Overcoming Biological Barriers in Neuroblastoma Therapy: The Vascular Targeting Approach with Liposomal Drug Nanocarriers

Overcoming Biological Barriers in Neuroblastoma Therapy: The Vascular Targeting Approach with Liposomal Drug Nanocarriers

Cytoglobin ameliorates the stemness of hepatocellular carcinoma via coupling oxidative‐nitrosative stress signals

Cell‐free protein synthesis: The transition from batch reactions to minimal cells and microfluidic devices

Contact Info

Product

Resources

About